Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Oct 14, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Oct 7, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Sep 17, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record1,08017 flagged findings
Reported transactions (Form 4)80since Mar 1, 2024 · and 7 other holdings
Corporate events (8-K)30since Nov 25, 2019
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
What the company does
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-05-06share offering or dilution eventrecentOpen filing ↗“…stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them…”
+1 more passage from the same document
- “…16.7 Employee stock purchase plan 0.2 0.1 15.5 16.8 19 11. Equity At-the-Market Offerings In February 2024, the Company entered into…”
- 2026-05-06capital return (buybacks/dividends)recentOpen filing ↗“…2026 $ — $ 218 $ 136 Effective annual interest rate (as of March 31, 2026) 9.2 % 7.3 % 5.5 % * In addition, OMERS will continue to…”
- 2026-05-06regulatory investigationrecentOpen filing ↗“…• suspend any of our ongoing clinical studies; • refuse to approve pending applications or supplements to approved…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
The 25 most recent filings (of 1,080)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Oct 14, 268-K ↗Current report · Entered a material agreement new
- Oct 7, 268-K ↗Current report · Entered a material agreement
- Sep 17, 268-K ↗Current report · Other events
- Sep 15, 26Form 144 ↗Notice of proposed sale
- Sep 2, 268-K ↗Current report · Other events
- Aug 19, 268-K ↗Current report · Other events
- Aug 14, 26SCHEDULE 13G ↗Passive stake · RTW Investments, LP · 7.9% · event on Jun 30, 26
- Aug 13, 26SCHEDULE 13G ↗Passive stake · AQR Capital Management, LLC · 6.7% · event on Jun 30, 26
- Aug 11, 268-K ↗Current report · Other events
- Aug 7, 26SCHEDULE 13G ↗Passive stake · STATE STREET CORPORATION · 6.3% · event on Jun 30, 26
- Aug 5, 2610-Q ↗Quarterly report
- Aug 4, 268-K ↗Current report · Results
- Aug 3, 26Form 144 ↗Notice of proposed sale
- Jul 31, 26SCHEDULE 13G/A ↗Passive stake · Vanguard Portfolio Management · 7.0% · event on Jun 30, 26 · amendment
- Jul 31, 26SCHEDULE 13G ↗Passive stake · Vanguard Capital Management · 5.1% · event on Jun 30, 26
- Jul 30, 26SCHEDULE 13G/A ↗Passive stake · BlackRock, Inc. · 8.3% · event on Jun 30, 26 · amendment
- Jul 6, 26Form 4 ↗Insider transaction
Notice of proposed sale · 3 Form 144 filingsshow all 3hide
- Jul 1, 26Form 144 ↗Notice of proposed sale
- Jun 15, 26Form 144 ↗Notice of proposed sale
- Jun 15, 26Form 144 ↗Notice of proposed sale
- Jun 15, 26Form 4 ↗Insider transaction
1,080 filings on record, the oldest from Jan 30, 14.
Listing the 25 most recent filings of the 1,080 on record.
13225
- Oct 14, 26Entered a material agreement8-K 1.01 ↗
- Oct 7, 26Entered a material agreement8-K 1.01 ↗
- May 18, 26A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Feb 12, 26Restructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
- Nov 4, 25Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- May 19, 25A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Jun 21, 24A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Jun 17, 24Entered a material agreement+1 more in the same filing8-K 1.01 ↗
- Oct 23, 23Entered a material agreement+1 more in the same filing8-K 1.01 ↗
7 senior executive changes2022 – 2023show all 7hide
- Sep 8, 23A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Jul 12, 23A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Jun 13, 23A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Mar 23, 23A senior executive left or was appointed8-K 5.02 ↗
- Mar 14, 23A senior executive left or was appointed8-K 5.02 ↗
- Nov 10, 22A senior executive left or was appointed8-K 5.02 ↗
- Sep 15, 22A senior executive left or was appointed8-K 5.02 ↗
- Jul 18, 22Entered a material agreement+4 more in the same filing8-K 1.01 ↗
- Jul 14, 22Entered a material agreement+2 more in the same filing8-K 1.01 ↗
11 older filings not shown · The record reaches back to Feb 25, 14.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- BlackRock, Inc.8.3%Jun 30, 26SCHEDULE 13G/A ↗1 earlier filing
- RTW Investments, LP7.9%Jun 30, 26SCHEDULE 13G ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
- Vanguard Portfolio Management7.0%Jun 30, 26SCHEDULE 13G/A ↗1 earlier filing
- AQR Capital Management, LLC6.7%Jun 30, 26SCHEDULE 13G ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
- STATE STREET CORPORATION6.3%Jun 30, 26SCHEDULE 13G ↗1 earlier filing
show 4 more holdershide
- Vanguard Capital Management5.1%Jun 30, 26SCHEDULE 13G ↗
- SANDS CAPITAL MANAGEMENT, LLC4.7%Dec 31, 24SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
- FMR LLC3.5%Dec 31, 25SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
- Wellington Management Group LLP2.7%Dec 31, 24SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Sep 15, THEODORE HUIZENGA filed notice of intent to sell up to $17K. It is filed under a scheduled plan (10b5-1), arranged in advance.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
After the notice, they sold $17K on Sep 15, per their Form 4. That is 100% of the shares announced so far, and the window is still open.
View notice (Form 144) ↗+2 more recent notices · 2 with a later sale
- Sep 15, 26Sell$17KTheodore Alan HuizengaSVP, Chief Accounting Officer↗
- Sep 3, 26Sell$2KTheodore Alan HuizengaSVP, Chief Accounting Officer↗
- Aug 3, 26Sell$117KHoward HornChief Financial Officer↗
- Aug 3, 26Sell$47KKarah Herdman ParschauerEVP and Chief Legal Officer↗
- Jul 1, 26Sell$156KHoward HornChief Financial Officer↗
- Jun 15, 26Sell$47KKarah Herdman ParschauerEVP and Chief Legal Officer↗
- Jun 15, 26Sell$50KCorazon (Corsee) D. Sanders↗
- Jun 1, 26Sell$111KHoward HornChief Financial Officer↗
- May 18, 26Sell$144KSHEHNAAZ SULIMAN↗
- May 5, 26Sell$9KEric CrombezEVP and Chief Medical Officer↗
- May 1, 26Sell$117KHoward HornChief Financial Officer↗
- Apr 1, 26Sell$98KHoward HornChief Financial Officer↗
There are 11 more transactions in this stretch.
Stock compensation, tax and giftsshow the 17 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- May 14, 26Compensationamount n/aDeborah Dunsire↗
- May 14, 26Compensationamount n/aDANIEL G WELCH↗
- May 14, 26Compensationamount n/aMICHAEL NARACHI↗
- May 14, 26Compensationamount n/aMatthew K Fust↗
- May 14, 26Compensationamount n/aSHEHNAAZ SULIMAN↗
- May 14, 26Compensationamount n/aCorazon (Corsee) D. Sanders↗
- May 14, 26Compensationamount n/aAmrit Ray↗
- Apr 22, 26Compensationamount n/aTheodore Alan HuizengaSVP, Chief Accounting Officer↗
- Apr 16, 26Compensationamount n/aHoward HornChief Financial Officer↗
- Apr 16, 26Compensationamount n/aEric CrombezEVP and Chief Medical Officer↗
- Apr 16, 26Compensationamount n/aErik HarrisEVP & Chief Commercial Officer↗
- Apr 16, 26Compensationamount n/aKarah Herdman ParschauerEVP and Chief Legal Officer↗
- Apr 16, 26Compensationamount n/aJohn Richard PinionSee Remarks↗
- Apr 16, 26Compensationamount n/aDennis Karl HuangSee Remarks↗
- Apr 16, 26Compensationamount n/aEMIL D KAKKISPresident & CEO↗
- Mar 2, 26Tax$23KDennis Karl HuangSee Remarks↗
- Mar 2, 26Tax$3KTheodore Alan HuizengaSVP, Chief Accounting Officer↗
The full record holds 207 transactions and goes back to Dec 30, 22.
Its sector and its market
Ultragenyx Pharmaceutical Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Ultragenyx Pharmaceutical Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Ultragenyx Pharmaceutical Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- Series with incidents in the period; the chart shows what could be kept.
- SEC records
- 1,080 documents on file, from Jan 30, 2014 to Oct 14, 2026.
- Company description
- Wikipedia, read on Sep 3, 2026.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.